Myomo (MYO) Cash from Investing Activities (2017 - 2025)
Myomo (MYO) posted Cash from Investing Activities of $189698.0 for Q3 2025, up 125.05% on a QoQ basis from -$757348.0 in Q2 2025, and down 93.29% year-over-year from $2.8 million in Q3 2024.
Myomo (MYO) Cash from Investing Activities (2017 - 2025) Analysis & Trends
Myomo's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $189698.0 for Q3 2025.
- Quarterly Cash from Investing Activities fell 93.29% year-over-year to $189698.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$3.8 million (down 197.68% YoY) and the FY2024 annual result came in at $259981.0, up 112.81% from the prior year.
- Cash from Investing Activities was $189698.0 for Q3 2025 at Myomo, up from -$757348.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $2.8 million in Q3 2024 and bottomed at -$3.5 million in Q1 2024.
- A 5-year average of -$256346.7 and a median of -$52793.0 in 2022 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 67882.92% in 2023, while the deepest fall reached 22831.05% in 2023.
- Myomo's Cash from Investing Activities stood at -$23935.0 in 2021, then soared by 85.86% to -$3385.0 in 2022, then soared by 67882.92% to $2.3 million in 2023, then tumbled by 158.98% to -$1.4 million in 2024, then jumped by 114.02% to $189698.0 in 2025.
- Business Quant data shows MYO's Cash from Investing Activities at $189698.0 in Q3 2025, -$757348.0 in Q2 2025, and -$1.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Myomo | 43.43 Mn | 24.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 189,698.00 |
| Sep 30, 2025 | 189,698.00 |
| Jun 30, 2025 | -757,348.00 |
| Jun 30, 2025 | -757,348.00 |
| Mar 31, 2025 | -1.90 Mn |
| Mar 31, 2025 | -1.90 Mn |
| Dec 31, 2024 | -1.35 Mn |
| Dec 31, 2024 | -1.35 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | -3.54 Mn |
| Mar 31, 2024 | -3.54 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Sep 30, 2023 | -1.32 Mn |
| Sep 30, 2023 | -1.32 Mn |
| Jun 30, 2023 | -2.96 Mn |
| Jun 30, 2023 | -2.96 Mn |